(Taken directly from the application) The Peptide Core Facility was initiated on 3/1/92, and over the past six-year period, the Facility has expanded and improved its services which now include: solid-phase fluorenylmethyloxycarbonyl (FMOC) peptide synthesis, HPLC purification, amino acid analysis, peptide/protein isolation, derivatization using reporter groups, and peptide conjugation for antibody preparation. These services are provided at cost to UMMS investigators, although the primary users are DERC members who receive a 65% discount from the grant subsidy. Use of the facility by DERC members has been consistent and sustained, involving about 40% of the 44-60 independent investigators in 1993 to 1998. There has been broad representation, with any one investigator receiving less than 12% of any of the six services. Over the past six-year period, DERC members received 1,430 peptide syntheses, 870 HPLC purifications, 784 amino acid analyses, 353 peptide conjugations, and 178 antibody productions. Performance evaluations in-house have been highly favorable, and Faculty Council has been supportive in regards to equipment needs. The results of a questionnaire predict equally strong usage of the facility by DERC members in the coming year. Goals for the future are to enhance our abilities to synthesize specialty peptides, including phospho/phosphono peptides, larger sized peptides, peptide libraries, and enzymatically resistant peptides. We also plan to improve quality control by utilizing mass spectrometer analysis. Current outside collaborative projects include the synthesis of ligands for gadolinium based nuclear magnetic resonance imaging of neuroendocrine peptide receptors and the synthesis of bichromophoric peptides of rigid structure in order to study mechanisms of photo-energy transfer.

Project Start
2002-06-04
Project End
2003-03-31
Budget Start
Budget End
Support Year
19
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Massachusetts Medical School Worcester
Department
Type
DUNS #
660735098
City
Worcester
State
MA
Country
United States
Zip Code
01655
Desai, Paurav B; San Agustin, Jovenal T; Stuck, Michael W et al. (2018) Ift25 is not a cystic kidney disease gene but is required for early steps of kidney development. Mech Dev 151:10-17
Ly, Socheata; Navaroli, Deanna M; Didiot, Marie-Cécile et al. (2017) Visualization of self-delivering hydrophobically modified siRNA cellular internalization. Nucleic Acids Res 45:15-25
Wang, Feng; McCannell, Kurtis N; Boškovi?, Ana et al. (2017) Rlim-Dependent and -Independent Pathways for X Chromosome Inactivation in Female ESCs. Cell Rep 21:3691-3699
Watkin, Levi B; Mishra, Rabinarayan; Gil, Anna et al. (2017) Unique influenza A cross-reactive memory CD8 T-cell receptor repertoire has a potential to protect against EBV seroconversion. J Allergy Clin Immunol 140:1206-1210
Wyss, Lena; Stadinski, Brian D; King, Carolyn G et al. (2016) Affinity for self antigen selects Treg cells with distinct functional properties. Nat Immunol 17:1093-101
Delong, Thomas; Wiles, Timothy A; Baker, Rocky L et al. (2016) Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion. Science 351:711-4
LeBlanc, Scott E; Wu, Qiong; Lamba, Pallavi et al. (2016) Promoter-enhancer looping at the PPAR?2 locus during adipogenic differentiation requires the Prmt5 methyltransferase. Nucleic Acids Res 44:5133-47
Wang, Feng; Shin, JongDae; Shea, Jeremy M et al. (2016) Regulation of X-linked gene expression during early mouse development by Rlim. Elife 5:
Kincaid, Eleanor Z; Murata, Shigeo; Tanaka, Keiji et al. (2016) Specialized proteasome subunits have an essential role in the thymic selection of CD8(+) T cells. Nat Immunol 17:938-45
Townsley, E; O'Connor, G; Cosgrove, C et al. (2016) Interaction of a dengue virus NS1-derived peptide with the inhibitory receptor KIR3DL1 on natural killer cells. Clin Exp Immunol 183:419-30

Showing the most recent 10 out of 707 publications